Show simple item record

dc.contributor.authorTesta, Nydia G
dc.contributor.authorHendry, Jolyon H
dc.contributor.authorMolineux, Graham
dc.date.accessioned2010-12-03T12:34:42Z
dc.date.available2010-12-03T12:34:42Z
dc.date.issued1985
dc.identifier.citationLong-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy., 5 (1):101-10 Anticancer Resen
dc.identifier.issn0250-7005
dc.identifier.pmid3888044
dc.identifier.urihttp://hdl.handle.net/10541/117108
dc.description.abstractLong-term bone marrow damage, characterised by stem, progenitor and stromal cell abnormalities is a frequent occurrence after cytotoxic treatments. The relative contributions of each of these components are difficult to analyse, especially in the case of patients who have received combined chemotherapy. The damage may be latent, and not manifested in low numbers of mature functional cells in the blood, but may become apparent as an hypoplastic syndrome at later times. Little tendency of recovery to normal parameters is seen in experimental animals and in patients.
dc.language.isoenen
dc.subjectCanceren
dc.subjectAnticancerous Agentsen
dc.subjectHaematopoiesisen
dc.subjectHaematopoietic Stem Cellsen
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents
dc.subject.meshBone Marrow
dc.subject.meshColony-Forming Units Assay
dc.subject.meshHematopoiesis
dc.subject.meshHematopoietic Stem Cells
dc.subject.meshHumans
dc.subject.meshMice
dc.subject.meshNeoplasms
dc.subject.meshRadiation Injuries
dc.subject.meshRadiation Injuries, Experimental
dc.subject.meshRadiotherapy
dc.subject.meshSpleen
dc.subject.meshTime Factors
dc.titleLong-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy.en
dc.typeArticleen
dc.contributor.departmentPaterson Laboratories, The Christie Hospital and Holt Radium Institute, Manchester, M20 9BX, UK.en
dc.identifier.journalAnticancer Researchen
html.description.abstractLong-term bone marrow damage, characterised by stem, progenitor and stromal cell abnormalities is a frequent occurrence after cytotoxic treatments. The relative contributions of each of these components are difficult to analyse, especially in the case of patients who have received combined chemotherapy. The damage may be latent, and not manifested in low numbers of mature functional cells in the blood, but may become apparent as an hypoplastic syndrome at later times. Little tendency of recovery to normal parameters is seen in experimental animals and in patients.


This item appears in the following Collection(s)

Show simple item record